Charles Schwab Investment Management Inc Xenon Pharmaceuticals Inc. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 192,242 shares of XENE stock, worth $8.35 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
192,242Holding current value
$8.35 Million% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding XENE
# of Institutions
222Shares Held
72.7MCall Options Held
336KPut Options Held
309K-
Avoro Capital Advisors LLC New York, NY5.4MShares$235 Million3.08% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.34MShares$188 Million1.31% of portfolio
-
Braidwell LP Stamford, CT3.61MShares$157 Million6.91% of portfolio
-
Janus Henderson Group PLC London, X03.58MShares$155 Million0.06% of portfolio
-
Capital International Investors Los Angeles, CA3.18MShares$138 Million0.02% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.7B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...